Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer
July 15, 2021 2:43 pmThe combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.
The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more